Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which...
Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%.
From other sites
at Nasdaq.com (Mar 25, 2015)
at CNBC.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at MarketWatch.com (Jan 14, 2015)
at Nasdaq.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs